Lundbeck Fined $125.6 Million by EU Drug Delay Probe

H. Lundbeck A/S, the Nordic region’s second-largest drugmaker, was fined 93.8 million euros ($125.6 million) by the European Union in its first case over pay-for-delay deals that held back sales of cheaper generic drugs.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.